A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302

Trial Profile

A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Pegvaliase (Primary)
  • Indications Phenylketonuria
  • Focus Therapeutic Use
  • Acronyms PRISM303
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 01 Dec 2015 Planned end date changed from 1 Sep 2016 to 1 Apr 2017, as reported by ClinicalTrials.gov.
    • 01 Dec 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017, as reported by ClinicalTrials.gov.
    • 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top